As of May 27, 2025, Sangamo Therapeutics Inc (SGMO) reports a Net Margin of -169.45%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Sangamo Therapeutics Inc's Net Margin
Over recent years, Sangamo Therapeutics Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -169.45% |
| 2023-12-31 | -146.30% |
| 2022-12-31 | -172.78% |
| 2021-12-31 | -161.07% |
| 2020-12-31 | -102.37% |
This slight downward trend highlights how Sangamo Therapeutics Inc manages its overall profitability and cost control over time.
Comparing Sangamo Therapeutics Inc's Net Margin to Peers
To better understand Sangamo Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Sangamo Therapeutics Inc (SGMO) | -169.45% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Krystal Biotech Inc (KRYS) | 30.69% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, Sangamo Therapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.